Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IW-9179 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo BID | PLACEBO_COMPARATOR | Placebo once in the morning and once in the evening. |
| IW-9179 QD AM + Placebo QD PM | EXPERIMENTAL | IW-9179 once in the morning and placebo once in the evening. |
| Placebo QD AM + IW-9179 QD PM | EXPERIMENTAL | Placebo once in the morning and IW-9179 once in the evening. |
| IW-9179 BID | EXPERIMENTAL | IW-9179 once in the morning and once in the evening |
| Name | Type | Description |
|---|---|---|
| IW-9179 | DRUG | - |
| Matching Placebo | DRUG | - |
Inclusion Criteria: * Patient is a male or non-pregnant, non-breastfeeding female, and is age 18 years or older at the time of the Screening Visit. * Patient has a confirmed diagnosis of type 1 or type 2 diabetes mellitus. * Patient has a diagnosis of DGP with no history or evidence of mechanical o...
IW-9179 is an investigational small molecule being developed for the treatment of diabetic gastroparesis, a gastrointestinal condition characterized by delayed stomach emptying in patients with diabetes. It is currently in clinical development and has not been approved by the FDA.
IW-9179 is being developed by Ironwood Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IRWD. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with diabetic gastroparesis.
IW-9179 is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational, meaning it has not yet received regulatory approval. Further studies would be needed to establish its safety and effectiveness for diabetic gastroparesis.
IW-9179 has been studied in a completed Phase 2 clinical trial identified as NCT02289846, titled "Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)." This randomized, double-blind, placebo-controlled trial enrolled 90 participants in the United States and included adults aged 18 years and older.
IW-9179 is the primary name used for this investigational drug in clinical research. No alternative names have been reported in the context of its development for diabetic gastroparesis. It is a distinct small molecule being evaluated by Ironwood Pharmaceuticals.